Featured Research

from universities, journals, and other organizations

Experimental Drug Decreases Age-Related Blood Vessel Stiffening

Date:
September 12, 2001
Source:
Johns Hopkins Medical Institutions
Summary:
An experimental drug may reverse stiffening of the cardiovascular system that occurs with aging, according to a national study led by Johns Hopkins physicians.

An experimental drug may reverse stiffening of the cardiovascular system that occurs with aging, according to a national study led by Johns Hopkins physicians.

Related Articles


In a group of older people with vascular stiffening, the drug, ALT-711, significantly reduced arterial pulse pressure, defined as the difference between systolic blood pressure (the upper number) and diastolic blood pressure (the lower number). It also improved the blood vessels' ability to stretch by about 14 percent. Results are to be reported in the Sept. 25 issue of Circulation, an American Heart Association journal, but were posted online Sept. 3. ALT-711 is manufactured by Alteon Inc., Ramsey, N.J.

Vascular stiffening and its related increase in the heart's workload is a "huge epidemiological problem," affecting about half of all individuals over age 60, says David A. Kass, M.D., lead author of the study and professor of medicine and biomedical engineering at Hopkins. "Many recent epidemiological studies have shown that pulse pressure is the leading risk factor for cardiovascular disease in the elderly," he says. Left untreated, the condition can lead to high blood pressure, congestive heart failure, heart attack and other disorders.

ALT-711 works by breaking up chemical links between sugar and proteins called advanced glycosylated (sugar-based) crosslink endproducts, or AGE. In the cardiovascular system, AGE results in a loss of artery elasticity. This leads to an increase in the blood pressure pulse and selective rise in the systolic pressure, putting patients at an increased risk of heart attack, heart failure and coronary artery disease.

The crosslinks form in patients with abnormal sugar control – such as diabetics – but also with normal aging. They particularly target long-lived proteins, like those that make up the structure of artery walls and are responsible for their ability to stretch. The more crosslinks, the stiffer the related tissues. This affects the cornea, bladder, arteries and possibly the heart. Diabetics face these problems earlier because of their altered body chemistry. These crosslinks also have recently been reported to affect neural function and may play a role in Alzheimer's disease.

"Prior drugs to treat this common type of blood pressure problem mostly have focused on lowering the mean or average pressure by relaxing the peripheral arteries that regulate resistance," says Kass. "ALT-711 appears to be different. It likely acts on the larger vessels that regulate stiffness. This may represent a novel therapeutic approach for patients with arterial stiffening associated with aging, diabetes and systolic hypertension."

During the trial, researchers at nine sites around the country studied 93 adults age 50 and up with measurably stiffened blood vessels and a systolic blood pressure of at least 140 mmHg. Patients took a drug tablet or a placebo once a day for eight weeks, during which researchers recorded their blood pressure, the flexibility or compliance of their arteries and blood flow through the heart, among other factors. ALT-711 was well tolerated in the patients who received the active drug.

Scientists are continuing to evaluate the medication and its ability to treat systolic hypertension in larger groups of patients.

Kass is a consultant to Alteon Inc. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

The study was supported by the National Institute on Aging and Alteon Inc. Other authors were Edward P. Shapiro, M.D., Miho Kawaguchi, M.D., and Anne R. Capriotti of Hopkins; Angelo Scuteri, M.D., Ph.D., and Edward G. Lakkata, M.D., of the NIA's Gerontology Research Center in Baltimore; and Robert C. deGroof, Ph.D., of Alteon Inc.

Kass, D.A., et al., "Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker," (Rapid Track) Circulation, 104: R8-R14.

Related Web sites:

Johns Hopkins' Division of Cardiology: http://www.cardiology.hopkinsmedicine.org

Alteon Inc.: http://www.alteonpharma.com


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Experimental Drug Decreases Age-Related Blood Vessel Stiffening." ScienceDaily. ScienceDaily, 12 September 2001. <www.sciencedaily.com/releases/2001/09/010906072321.htm>.
Johns Hopkins Medical Institutions. (2001, September 12). Experimental Drug Decreases Age-Related Blood Vessel Stiffening. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2001/09/010906072321.htm
Johns Hopkins Medical Institutions. "Experimental Drug Decreases Age-Related Blood Vessel Stiffening." ScienceDaily. www.sciencedaily.com/releases/2001/09/010906072321.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins